TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline [Yahoo! Finance]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Yahoo! Finance
R&D Investments : R&D expenses increased to $22.4 million in Q4 and $88.2 million for the full year, reflecting clinical trial and personnel costs. G&A Expenses : General and administrative expenses slightly increased to $6.2 million in Q4 and $26.4 million for the full year. Net Loss : Net loss for Q4 was $19.6 million, with a full-year net loss of $89.2 million, including net interest income. Cash Position : Cash, cash equivalents, and marketable securities totaled $192.0 million, funding operations into 2026. Share Count : Issued and outstanding shares totaled 47,829,529 as of December 31, 2023. Warning! GuruFocus has detected 6 Warning Signs with TCRX. On March 6, 2024, TScan Therapeutics Inc ( NASDAQ:TCRX ) released its 8-K filing , announcing its financial results for the fourth quarter and full year ended December 31, 2023, along with a comprehensive business update. The biopharmaceutical company, which specializes in T-cell receptor (TCR) engineered T cell therapi
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingGlobeNewswire
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswire
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.MarketBeat
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting [Yahoo! Finance]Yahoo! Finance
TCRX
Earnings
- 11/9/23 - Beat
TCRX
Sec Filings
- 4/23/24 - Form SC
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- TCRX's page on the SEC website